TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject capable of giving consent~* Age 18-80~* Scheduled for open colorectal resection at Cleveland Clinic main campus (with preoperative appointment scheduled at least five days before date of surgery)~Exclusion Criteria:~* Patient does not speak English~* Patient with substance-use disorder (including alcohol)~* Patient diagnosed with major depression~* Patient currently taking opioids~* Previous long-term opioid use (\> 3 months)~* Previous opioid use with a dose of \>100 milligram morphine equivalent (MME)~* Patient has pain-related disorder (e.g. fibromyalgia, sympathetic dystrophy, etc.)~* Documented allergy to pain medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): The control arm will receive no intervention and will follow standard of care for post-operative pain management.
- PGx-guided (Type: EXPERIMENTAL): The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. End stage renal disease (ESRD) patients on hemodialysis for at least 3 months.~2. Serum C reactive protein level of ≥ 0.8 mg/dl.~3. Serum albumin \< 3.8 g/dl (BCG).~4. Signing a written informed consent form.~5. Willingness and ability to comply with the FDA-mandated S.T.E.P.S ® program.~6. Age \> 18 years.~Exclusion Criteria:~1. Pregnant and/ or lactating female.~2. Active infection within the previous 8 weeks requiring administration of antibiotics.~3. Patients receiving systemic immunosuppressive therapy.~4. Patients with HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thalidomide (Type: ACTIVE_COMPARATOR): 1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~2. Serum C reactive protein level of ≥ 0.8 mg/dl~3. Serum albumin \< 3.8 g/dl (BCG)~4. Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide.
- No Drug (Type: PLACEBO_COMPARATOR): 1. 12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~2. Serum C reactive protein level of ≥ 0.8 mg/dl~3. Serum albumin \< 3.8 g/dl (BCG)~4. Patients will receive Placebo (Sugar pill) for a period of 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Addiction Risk: Mindset Induction Effect on Brief Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* student status at University of Konstanz~* risky alcohol use in past 12 months~Exclusion Criteria:~* acute psychosis, acute suicidality, illiteracy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Induction of Implemental Mindset (Type: EXPERIMENTAL): Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer \& Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
- Induction of Deliberative Mindset (Type: EXPERIMENTAL): Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer \& Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
- Control (Type: NO_INTERVENTION): Participants will revive no induction of any mindset.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dichoptic Virtual Reality Therapy for Amblyopia in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Interpupillary distance of 60-66 mm~* Age 15-40~* Anisometropic amblyopia or strabismic amblyopia~* Best corrected visual acuity of 20/30 or worse in the amblyopic eye~* No prior therapeutic use of the software~* No other ongoing therapies including patching or recent eye muscle surgery~* No vested interest in the product~* Ability attend visits and complete the training session, and to stop the intervention after the specified intervention period~Exclusion Criteria:~* Stimulus-deprivation amblyopia.~* Organic lesions of the eye preventing the establishment of good vision (eg. media opacities, abnormalities in the fundus or optic nerve).~* Lesions of the brain preventing the establishment of good vision (eg. cortical visual impairment).~* Establishment of normal vision by refractive adaptation (wearing glasses after presentation).~* Patients diagnosed with Photosensitive Epilepsy.~* Inability to comply with the follow-up visits required.~* History of pathologic nystagmus (congenital or sensory).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Patching therapy (Type: ACTIVE_COMPARATOR): Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
- Dioptic (non-dichoptic) therapy (Type: ACTIVE_COMPARATOR): Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
- Dichoptic therapy (Type: EXPERIMENTAL): Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with severe aortic stenosis (AVA \< 1.0 cm2)~* Left ventricular hypertrophy~* EF ≥ 45%~* NYHA functional class ≥ 2~* Ambulatory (able to perform a 6 minute walk test)~* Normal sinus rhythm~* 18 years of age and older~* Able and willing to comply with all the requirements for the study~Exclusion Criteria:~* Need for ongoing nitrate medications~* SBP \< 110mmHg or MAP \< 75mmHg~* Moderately severe or severe mitral regurgitation~* Moderately severe or severe aortic regurgitation~* Creatinine clearance \< 30 mL/min~* Increased risk of priapism~* Retinal or optic nerve problems or unexplained visual disturbance~* If a subject requires ongoing use of an alpha antagonist typically used for benign prostatic hyperplasia (BPH) (prazosin, terazosin, doxazosin, or tamsulosin), SBP \< 120 mmHg or MAP \< 80 mmHg is excluded~* Need for ongoing use of a potent CYP3A inhibitor or inducer (ritonavir, ketoconazole, itraconazole, rifampin)~* Cirrhosis~* Pulmonary fibrosis~* Current or recent (≤ 30 days) acute coronary syndrome~* O2 sat \< 90% on room air~* Females that are pregnant or believe they may be pregnant~* Any condition which the PI determines will place the subject at increased risk or is likely to yield unreliable data~* Unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Laparoscopic Revision of an Enlarged Gastric Outlet After Gastric Bypass

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female patients 18 to 65 years old who are able to provide informed consent for this surgical procedure~2. Patients who have previously had a laparoscopic or open Roux-en-Y gastric bypass surgery~3. Patients who have regained or failed to lose their excess body weight~Exclusion Criteria:~1. Inability to provide informed consent~2. Patients who have dilated gastric pouch.~3. Patients who have a gastrogastric fistula.~4. Patients who are pregnant or plan to become pregnant during the follow up period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Revision of gastric bypass (Type: EXPERIMENTAL): A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and sign institutional review board/independent ethics committee-approved informed consent form (ICF) prior to any study-specific evaluation~* Life expectancy of at least 3 months~* ECOG performance status of 0 to 1~* ≥ 18 years at the time ICF is signed~* Adequate hematological and biological function~* Histologically or cytologically confirmed solid tumor malignancy (Part 1 only)~* Histologically or cytologically confirmed stage IIIb/IV NSCLC (Part 2 only)~Exclusion Criteria:~* Symptomatic central nervous system metastases~* Concomitant treatment with prohibited medications, e.g. other chemotherapy, radiation, hormonal treatment (excepting corticosteroids), or immunotherapy ≤ 14 days prior to CO-1.01 treatment~* Treatment with a previous regimen of CO-1.01~* Participation in another therapeutic clinical study within 14 days of enrollment or during this clinical study~* Surgical procedures ≤ 14 days prior to CO-1.01 administration~* History of allergy to gemcitabine, gemcitabine elaidate or eggs~* Known allergic/hypersensitivity reaction to cisplatin, other platinum agent, or platinum containing compounds~* Peripheral neuropathy ≥ Grade 1~* Females who are pregnant or breastfeeding~* Refusal to use adequate contraception for fertile patients~* Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study~* Any other reason the investigator considers the patient should not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CO-1.01 and Cisplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Structured Group Education on Quality of Life and Glycemic Control in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 1 diabetes~Exclusion Criteria:~* serious diabetic complications, such as to interfere with physical functioning (e.g., lower limb amputation, renal failure requiring dialysis, blindness)~* Illiteracy

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Structured Group education (Type: EXPERIMENTAL): Six weekly interactive group sessions of 4 hours each, providing information and developing skills for diabetes self-management, including eating habits, food composition, calculation of bolus insulin, information on physical exercise, blood glucose self-monitoring, management of hypoglycemia.
- Individual education (Type: OTHER): Usual care (individual consultations as routinely performed)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of ovarian cancer~  * Any stage disease~* Must be between 2-24 months post-primary treatment (surgery) following initial diagnosis and/or have a recurrence of ovarian cancer within the past 24 months (irrespective of current treatment status)~* Began a new chemotherapy treatment regimen within the past 4 weeks or planning to begin new chemotherapy treatment regimen within the next 4 weeks~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Physically able to attend the intervention classes~* Able to understand written and spoken English~* Agree to keep psychiatric medications and doses stable during study intervention~* No medical contraindications reported by the attending physician~* No bipolar disorder, schizophrenia, psychotic depression, or any other psychotic disorder~* No usage of illicit drugs~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 3 months since prior yoga practice

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Yoga classes plus home yoga practic (Type: EXPERIMENTAL): None
- home yoga practice alone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compressive Stockings Therapy After TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving a total knee replacement~* Written consent of the study participant~Exclusion Criteria:~* Peripheral arterial disease II, III or IV~* Diabetes mellitus~* Systemic inflammatory diseases~* Benign or malignant neoplasms~* Revision interventions~* Right heart failure~* pulmonary edema~* Open / chronic skin lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Compressive stockings group (Type: ACTIVE_COMPARATOR): Group receives postoperatively compressive stockings for a period of 6 weeks.
- Control group (Type: NO_INTERVENTION): The control group is treated without compressive stockings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NAFLD and/or NASH~* Subject aged 18 and older~* Non-pregnant - Self-reported~* Subject with decision making capacity to understand and consent to study procedures~* Ability to follow study related activities regarding medications, diet and exercise~Exclusion Criteria:~* Without diagnosis of NAFLD or NASH~* History of liver disease from other causes, including but not limited to hepatitis, autoimmune, alcohol use, fatty liver of pregnancy, Wilson's disease, primary or secondary hemochromatosis~* Patients aged less than 18 years~* Self-reported pregnant patients~* Inability to understand, follow and consent to study procedures~* Hepatic decompensation defined as gastrointestinal bleeding, ascites, hepatic encephalopathy~* Inability to engage in exercise~* Currently immunocompromised or taking immunosuppressive drugs~* Milk protein allergy~* Recent or active chemotherapy for malignancy~* Gastrointestinal malignancy~* Gastrointestinal disease such as Ulcerative Colitis, Crohn's Disease as these alter the microbiome~* Recent antibiotic therapy (within 6 months)~* Known allergy to probiotics~* History of major gastrointestinal surgery such as resection of the colon~* No concomitant use of probiotic from any source (i.e., kefir, certain yogurts, live culture, sauerkraut)~* Liver scan \>2 months prior to enrollment~* Weight loss \>5 pounds in the last 2 months~* Any implanted battery operated device (i.e. AICD, pacemaker, loop recorder, cochlear implant)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group: Probiotic (Type: ACTIVE_COMPARATOR): Probiotic 1 billion units Supplement Once Daily
- Control Group: Placebo (Type: PLACEBO_COMPARATOR): Placebo Capsule Once Daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 years of age~* Aneurysmal subarachnoid hemorrhage, proven on CT angiogram or digital subtraction angiography~* Aneurysm treated, either by endovascular embolization or surgical clip ligation~* Evidence of increased velocities on transcranial dopplers (TCDs) and/or radiographic evidence of vasospasm as seen on angiogram~* Cerebral vasospasm as demonstrated by patient's clinical exam (new focal deficit or change in mental status not attributable to any other cause)~Exclusion Criteria:~* Recurrent subarachnoid hemorrhage~* Untreated ruptured aneurysm, for any reason~* Patients who die prior to treatment for aneurysm~* Patients who are not able to complete at least 6 months of follow-up~* Patients who are admitted already in vasospasm (i.e. a delayed admission)~* Creatinine clearance less than 20 ml/min~* Women with a positive pregnancy test or who are lactating~* Other comorbidity which may adversely affect patient outcome, at the discretion of the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Milrinone (Type: ACTIVE_COMPARATOR): Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility